Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. (Q39204978)

10 September 2017

title

Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. (English)

1 reference

10 September 2017

author

Gabriela Salinas-Riester

5

object named as

Gabriela Salinas-Riester

1 reference

10 September 2017

4

Lennart Opitz

1 reference

10 September 2017

Sandra von Hardenberg

3

object named as

Sandra von Hardenberg

1 reference

10 September 2017

Daria Witt

1

1 reference

10 September 2017

Peter Burfeind

2

1 reference

10 September 2017

Felix Bremmer

6

1 reference

10 September 2017

Stefan Schweyer

7

1 reference

10 September 2017

Paul Thelen

8

1 reference

10 September 2017

Jürgen Neesen

9

1 reference

10 September 2017

Silke Kaulfuss

10

1 reference

10 September 2017

language of work or name

English

0 references

publication date

24 January 2013

1 reference

10 September 2017

1 reference

10 September 2017

volume

34

1 reference

10 September 2017

issue

5

1 reference

10 September 2017

page(s)

1115-1124

1 reference

10 September 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Epigenetics in cancer: targeting chromatin modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Chromatin remodeling and cancer, Part I: Covalent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Molecular and therapeutic potential and toxicity of valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Cyclin D2 is overexpressed in proliferation centers of chronic lymphocytic leukemia/small lymphocytic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Cyclin D as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Antitumoral effects of calcitriol in basal cell carcinomas involve inhibition of hedgehog signaling and induction of vitamin D receptor signaling and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Pluripotent embryonic stem cells and multipotent adult germline stem cells reveal similar transcriptomes including pluripotency-related genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Prostate cancer in a transgenic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/CARCIN/BGT019

21 January 2018

Identifiers

DOI

10.1093/CARCIN/BGT019

1 reference

10 September 2017

1 reference